5-[3-(4-phenylpiperazinyl)propoxy]-3,4-dihydrocarbostyril monohydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5-[3-(4-phenylpiperazinyl)propoxy]-3,4-dihydrocarbostyril monohydrochloride
• 英文别名: 5-[3-(4-phenylpiperazin-1-yl)propoxy]-3,4-dihydro-1H-quinolin-2-one;hydrochloride
• 化学式: C₂₂H₂₇N₃O₂*ClH
• 分子量: 401.936
• InChiKey: JSRIHBJICUOJDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.58
• 重原子数：
  28.0
• 可旋转键数：
  6.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  44.81
• 氢给体数：
  1.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  5-羟基-3,4-二氢-2-喹啉酮 在 氢氧化钾 、 sodium iodide 作用下， 以 异丙醇 、 乙腈 为溶剂， 反应 18.0h， 生成 5-[3-(4-phenylpiperazinyl)propoxy]-3,4-dihydrocarbostyril monohydrochloride
  参考文献：
  名称：

  Studies on 2(1H)-quinolinone derivatives as neuroleptic agents. I. Synthesis and biological activities of (4-phenyl-1-piperazinyl)-propoxy-2(1H)-quinolinone derivatives.

  摘要：

  为了开发一种新型的神经安定药物，合成了一系列ω-(4-苯基-1-哌嗪基)-烷氧基-2(1H)-喹啉酮衍生物，并测试了它们的抗甲基苯丙胺和抗肾上腺素活性。大多数衍生物在3-(3, 4-二羟基苯基)-L-天冬氨酸（L-DOPA）和甲基苯丙胺处理的小鼠的跳跃行为测试中显示出强效的抗甲基苯丙胺活性，或者在甲基苯丙胺处理的小鼠的致死性测试中表现出显著效果。它们还表现出相对较高的抗肾上腺素效能，这取决于取代基在4-苯基-1-哌嗪基上的性质或数量；其中一些化合物在小鼠中仅引起轻微的强直症。在这些化合物中，7-{3-[4-(2, 3-二甲基苯基)-1-哌嗪基]丙氧基}-2(1H)-喹啉酮（OPC-4392），被认为是一种多巴胺自受体激动剂，已被选定用于进一步研究。同时，本文也讨论了结构-活性关系。

  DOI：

  10.1248/cpb.36.4377

文献信息

• Pharmaceutically useful carbostyril derivatives
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04734416A1

  公开（公告）日：1988-03-29

  Carbostyril derivatives having antihistamic action and central nervous controlling action are useful as antihistamic agents or central nervous controlling agents. The derivatives are represented by the general formula, ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkynyl group having 2 to 4 carbon atoms or a phenylalkyl group having an alkylene group containing 1 to 4 carbon atoms; R.sup.2 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or a phenyl group; R.sup.3 is a hydrogen atom, a hydroxy group, an alkyl group having 1 to 4 carbon atoms, an alkanolyoxy group having 1 to 4 carbon atoms or a 3,4,5-trimethoxybenzoyloxy group; R.sup.4 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; R.sup.5 is a cycloalkyl group having 3 to 8 carbon atoms, a phenyl group (which may have 1 to 3 substituted groups selected from the group consisting of halogen atoms, alkyl groups having 1 to 4 carbon atoms and alkoxy groups having 1 to 4 carbon atoms), an alkyl group having 1 to 4 carbon atoms (having one substituted group such as a hydroxy group, a phenyl group or an alkanoyloxy group having 1 to 4 carbon atoms), an alkanoyl group having 1 to 4 carbon atoms or benzoyl group; X is a halogen atom; n is 0, or an integer of 1 or 2; Q is an integer of 2 or 3, l and m are respectively an integer of 0 or 1-6, but the sum of l and m should not exceed 6; the carbon-carbon bond at the 3- and 4-positions in the carbostyril skeleton is a single or double bond; and the substituted position of the side chain of ##STR2## is any one of the 4-, 5-, 6-, 7- or 8-positions.

  卡波司酯衍生物具有抗组胺作用和中枢神经控制作用，可用作抗组胺剂或中枢神经控制剂。这些衍生物由通式所代表，其中R.sup.1是氢原子、具有1至6个碳原子的烷基基团、具有2至4个碳原子的烯基基团、具有2至4个碳原子的炔基基团或含有1至4个碳原子的烷基基团的苯基基团；R.sup.2是氢原子、具有1至4个碳原子的烷基基团或苯基团；R.sup.3是氢原子、羟基、具有1至4个碳原子的烷基基团、具有1至4个碳原子的烷酰氧基团或3,4,5-三甲氧基苯甲酰氧基团；R.sup.4是氢原子或具有1至4个碳原子的烷基基团；R.sup.5是具有3至8个碳原子的环烷基基团、苯基（可能有1至3个卤素原子、具有1至4个碳原子的烷基基团和具有1至4个碳原子的烷氧基团中选择的取代基）、具有1至4个碳原子的烷基基团（具有一个取代基，如羟基、苯基或具有1至4个碳原子的烷酰氧基团）、具有1至4个碳原子的烷酰基或苯甲酰基；X是卤素原子；n为0或1或2的整数；Q为2或3的整数，l和m分别为0或1至6的整数，但l和m的总和不应超过6；卡波司酯骨架中3-位和4-位的碳-碳键为单键或双键；以及##STR2##的侧链的取代位置为4-、5-、6-、7-或8-位中的任意一个。
• Carbostyril derivatives and pharmaceutical preparations containing same
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US04824840A1

  公开（公告）日：1989-04-25

  Carbostyril derivatives having antihistaminic action and central nervous controlling action are useful as antihistaminic agents or central nervous controlling agents. The derivatives are represented by the general formula, ##STR1## wherein R.sup.1 is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkynyl group having 2 to 4 carbon atoms or a phenylalkyl group, an alkylene group containing 1 to 4 carbon atoms; R.sup.2 is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or a phenyl group; R.sup.3 is a hydrogen atom, a hydroxy group, an alkyl group having 1 to 4 carbon atoms, an alkanoyloxy group having 1 to 4 carbon atoms or a 3,4,5-trimethoxybenzoyloxy group; R.sup.4 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms; R.sup.5 is a cycloalkyl group having 3 to 8 carbon atoms, a phenyl group (which may have 1 to 3 substituted groups selected from the group consisting of halogen atoms, alkyl groups having 1 to 4 carbon atoms and alkoxy groups having 1 to 4 carbon atoms), an alkyl group having 1 to 4 carbon atoms (having one substituted group such as a hydroxy group, a phenyl group or an alkanoyloxy group having 1 to 4 carbon atoms), an alkanoyl group having 1 to 4 carbon atoms or benzoyl group; X is a halogen atom; n is 0, or an integer of 1 or 2; Q is an integer of 2 or 3, l and m are respectively an integer of 0 to 1-6, but the sum of l and m should not exceed 6; the carbon-carbon bond at the 3- and 4-positions in the carbostyril skeleton is a single or double bond and; the substituted position of the side chain of ##STR2## is any one of the 4-, 5-, 6-, 7- or 8-positions.

  羧基苯基吡啶衍生物具有抗组胺作用和中枢神经控制作用，可用作抗组胺剂或中枢神经控制剂。该衍生物由通式## STR1 ##表示，其中R.sup.1是氢原子，具有1至6个碳原子的烷基，具有2至4个碳原子的烯基，具有2至4个碳原子的炔基或苯基烷基，含有1至4个碳原子的烷基，R.sup.2是氢原子，具有1至4个碳原子的烷基或苯基，R.sup.3是氢原子，羟基，具有1至4个碳原子的烷基，具有1至4个碳原子的烷酰氧基或3,4,5-三甲氧基苯甲酰氧基，R.sup.4是氢原子或具有1至4个碳原子的烷基，R.sup.5是具有3至8个碳原子的环烷基，苯基（可能具有1至3个取代基，所述取代基选自卤原子，具有1至4个碳原子的烷基和具有1至4个碳原子的烷氧基），具有1至4个碳原子的烷基（具有一个取代基，例如羟基，苯基或具有1至4个碳原子的烷酰氧基），具有1至4个碳原子的烷酰基或苯甲酰基; X是卤原子; n为0或1或2的整数; Q为2或3的整数，l和m分别为0至1-6的整数，但l和m的总和不应超过6;羧基吡啶骨架中3-和4-位置的碳-碳键是单键或双键; ## STR2 ##的侧链的取代位置是4-，5-，6-，7-或8-位置之一。
• CAKAHO, KADZUO;FUDZIOKA, TAKAFUMI;OSIRO, YASUO;NAKAGAVA, KADZUYUKI
  作者：CAKAHO, KADZUO、FUDZIOKA, TAKAFUMI、OSIRO, YASUO、NAKAGAVA, KADZUYUKI

  DOI：——

  日期：——
• US4734416A
  申请人：——

  公开号：US4734416A

  公开（公告）日：1988-03-29
• US4824840A
  申请人：——

  公开号：US4824840A

  公开（公告）日：1989-04-25